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strains, but the improved performance in the
present study may also be a result of the devel-
opment of the Vitek 2 database. Identification of
C. guilliermondii and Candida lusitaniae was prob-
lematic, both in the study by Graf et al. [8] and in
the present study, whereas all C. glabrata isolates
were identified without difficulty. This is in
contrast to the study by Massonet et al. [9], in
which most difficulties were encountered with
C. glabrata. The reason for this discrepancy is
unknown. As in the study by Graf et al. [8], the
present database was unable to separate Candida
inconspicua and Candida norvegensis.
Conventional identification methods are still
considered to be the reference standard for the
identification of yeast isolates, but are laborious
and time-consuming, and are suited better to
research than to clinical laboratories. The Vitek 2
system identifies most clinically important Candida
spp. reliably within 15 h, and appears to be an
excellent alternative identification method for clin-
ical laboratories performing fungal diagnostics.
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ABSTRACT
Brucella melitensis is highly pathogenic and con-
stitutes a serious risk to public health. In Argen-
tina, biovar 1 has been isolated from infected
animals, but the Rev.1 strain vaccine is not
authorised for use. This report describes nine
atypical B. melitensis isolates obtained from hu-
mans. These isolates grew slowly, produced small
colonies and were susceptible to penicillin and
dyes, similar to the B. melitensis Rev.1 vaccine
strain, but were inhibited by streptomycin
2.5 mg ⁄L. The isolation of such atypical B. meli-
tensis variants has never been reported from
animals in Argentina, and could indicate the
emergence of a new mutant variant.
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Although the organisms constituting the genus
Brucella are highly homogeneous, the genus is
classified currently into six nomen species: Bru-
cella abortus, Brucella suis, Brucella melitensis, Bru-
cella canis, Brucella ovis and Brucella neotomae [1–3].
This taxonomic scheme correlates somewhat with
the preferential natural host, although the first
three species can also infect other animals [4].
Differences in virulence have been observed, and
the apparent rank virulence order shown in
guinea-pigs seems to be similar to that in humans:
i.e., B. melitensis > > B. suis > > B. abortus [5]. Each
species is subdivided into biovars on the basis of
cultural, biochemical and serological differences,
but the three biovars of B. melitensis are distin-
guished solely by their immunochemical reac-
tions with monospecific anti-lipopolysaccharide
(LPS) A and M-determinant sera [6]. Isolation of
atypical B. melitensis variants in Israel, and of dye-
sensitive strains in various countries, has been
reported, indicating that differences are not
limited to the agglutination pattern [7,8].
The Argentine National Human Brucellosis
Network (NHBN) at the ANLIS Dr C.G. Malbra´n
(Buenos Aires, Argentina) studied 118 B. melitensis
isolates from humans during the period 1994–
2004. The isolates were obtained from clinical
laboratories in Argentine provinces, and were sent
to the NHBN headquarters for characterisation.
The present study reports the isolation and typing
of nine B. melitensis isolates with atypical pheno-
typic characteristics that could indicate the emer-
gence of a new mutant variant. All nine atypical
isolates were differentiated from other Gram-
negative organisms on the basis of morphology,
motility, lactose fermentation on MacConkey agar,
acid production on agar containing glucose, hae-
molysis on blood agar, catalase, oxidase and
urease (Christensen method) reactions, and nitrate
and citrate reduction. Rough ⁄ smooth phase vari-
ation was observed using obliquely reflected light,
suspending a colony in acriflavine, and by stain-
ing colonies with crystal violet [6].
After the isolates were identified as members of
the genus Brucella, their species identification and
biovar were established according to the recom-
mendations of the International Committee on
Bacterial Nomenclature (ICBN), Subcommittee on
Taxonomy of the Genus Brucella [2]. Serum and
CO2 requirements, H2S production, and growth in
the presence of thionin (20 mg ⁄L), basic fuschin
(20 mg ⁄L), safranin O (100 mg ⁄L), erithrytol
(1 g ⁄L), penicillin (5000 IU ⁄mL) and streptomy-
cin (2.5 mg ⁄L) added to Brucella Agar (BBL
Microbiology Systems, Cockeysville, MD, USA)
were determined. Growth patterns on thionin
blue and malachite green (2 mg ⁄L) were investi-
gated, both with and without the presence of CO2
5% v ⁄ v. Urease tests (Bauer’s method) and
agglutination with polyclonal monospecific anti-
A, -M and -R antisera were performed [6].
Susceptibility to Brucella phages was determined
using Tb, R ⁄C, Wb and Iz phages at 1 and 104
routine test dilution (RTD) [9]. Reference strains
B. abortus 544-2, B. suis 1330, B. melitensis biovar 1
16 M, biovar 2 63 ⁄ 9 and biovar 3 Ether, and
B. melitensis Rev.1, were included in each test as
controls. Finally, PCR-RFLP (restriction fragment
length polymorphism) analysis was performed by
digesting the amplified omp25 gene with EcoRV,
and the amplified rpsl gene with NciI [10,11].
Brucellosis is not a sustainable disease in
humans, and the source of infection always
resides in domestic or wild animals, or their
derived products. However, new Brucella strains
and species may emerge as those existing already
adapt to social and agricultural changes [12–14].
In Argentina, the sheep population (c. 15 million)
is concentrated mainly in the south and north-east
of the country, while goats (c. 4 million) are
located mostly in the north-west. Surveys
revealed a 0.5–0.8% prevalence of caprine bru-
cellosis in the north-western provinces, with the
isolation of B. melitensis biovar 1 from infected
goats, although the use of the B. melitensis Rev.1
vaccine has not been authorised. Ovine brucello-
sis caused by B. ovis was found in regions where
sheep are located, but B. melitensis has only been
isolated from a few sheep [15].
Of the 118 B. melitensis isolates from humans,
107 (90.67%) belonged to biovar 1, two (1.69%)
belonged to biovar 3, and nine (7.6%) were
atypical. Isolate 874 was characterised in 1986 at
the Pan American Zoonosis Center (PAHO ⁄
WHO) as atypical B. melitensis biovar 1 (Table 1).
To check its stability, a suspension containing 108
CFU ⁄mL was injected into two guinea-pigs and
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was recovered after 6 weeks from their spleens.
The isolates had the same phenotypical charac-
teristics as the original strain, indicating that the
isolate could be considered stable following
animal passage.
All nine atypical isolates were smooth, grew
slowly, produced small colonies and were sus-
ceptible to penicillin and dyes, similar to the
Rev.1 vaccine strain, but were inhibited by strep-
tomycin 2.5 mg ⁄L (Table 2). A slight increase in
the growth pattern on basic fuchsin was observed
when CO2 5% v ⁄ v was present during incuba-
tion, and also when sterile equine serum 5% v ⁄ v
was added to the basal medium. However,
growth was inhibited by thionin blue and mala-
chite green, even in the presence of CO2. Of the
nine atypical B. melitensis isolates, eight were
identified as biovar 1 and one as biovar 2, based
on a difference in the quantitative distribution of
the A and M antigens.
In Argentina, only B. melitensis biovar 1 has
been isolated from animals, while two cases of
infection with biovar 3 have been reported in
humans [16] (IX Congreso de Argentino de
Microbiologı´a, Buenos Aires, 2001, abstract 220),
probably because infected animals are diagnosed
mainly by serological tests. The nine patients in
the present study (Table 1) were hospitalised with
fever and weight loss as the main symptoms. A
girl (aged 7 years, isolate 290) relapsed 6 months
after completing treatment and the same strain
was isolated.
PCR-RFLP of the omp25 gene with EcoRV
showed that all nine isolates were true B. meliten-
Table 1. Clinical and epidemiological data for the nine atypical Brucella melitensis isolates
Strain Argentina province Source Year isolated Gender Age (years) Main symptoms Epidemiology
874 Jujuy Blood · 2 1986 M ND ND ND
290a Jujuy Bone-marrow · 1 1996 F 7 Fever, pancytopenia, arthralgias, weigh loss Ingestion of goat cheese
429 Co´rdoba Blood · 2 2000 M ND ND ND
489 Catamarca Blood · 2 2000 F 5 Fever, arthralgias, hepatosplenomegaly Ingestion of goat cheese
497 S. del Estero Blood · 3 2000 M 18 Fever, weight loss Rural worker
544 Jujuy Bone-marrow · 1 2002 F 27 Fever, weight loss, asthenia Bolivian farmer
582 Salta Blood · 2 2002 ND ND Hepatosplenomegaly ND
605 Tucuma´n Blood · 3 2002 M 8 ND Goat handling
712 Jujuy Blood · 2 2003 M 30 Fever, weight loss, pancytopenia Bolivian farmer
aIsolated from the same patient at three different times.
ND, no data.
Table 2. Differential characteristics of the atypical Brucella melitensis isolates in comparison with species belonging to the
genus Brucellaa
Strain CO2 requirement H2S production
Growth on media with
Agglu-
tination
in serag Lysis by phagesh
Thioninb Basic Fuchsinb Safranin O c Streptomycind Penicilline Ureasef A M Tb Wb Iz
290 IBS (–) (–) (+ ⁄ –) (–) (–) (–) (–) (–) (–) (+) (–) (–) (+ ⁄ –)
429 IBS (–) (–) (+) (–) (–) (–) (–) (–) (+) (–) (–) (+ ⁄ –) (+)
489 IBS (–) (–) (+ ⁄ –) (–) (–) (–) (–) (–) (–) (+) (–) (–) (+ ⁄ –)
497 IBS (–) (–) (+) (–) (–) (–) (–) (–) (–) (+) (–) (–) (+ ⁄ –)
544 IBS (–) (–) (+ ⁄ –) (–) (–) (–) (–) (–) (–) (+) (–) (+ ⁄ –) (+)
582 IBS (–) (–) (+ ⁄ –) (–) (–) (–) (–) (–) (–) (+) (–) (+ ⁄ –) (+ ⁄ –)
605 IBS (–) (–) (+ ⁄ –) (–) (–) (–) (–) (–) (–) (+) (–) (+ ⁄ –) (+ ⁄ –)
712 IBS (–) (–) (+ ⁄ –) (–) (–) (–) (–) (–) (–) (+) (–) (–) (+ ⁄ –)
874 IBS (–) (–) (+ ⁄ –) (–) (–) (–) (–) (–) (–) (+) (–) (+ ⁄ –) (+ ⁄ –)
B. melitensis 16 Mi (–) (–) (+) (+) (+) (–) (+) (+) (–) (+) (–) (+ ⁄ –) (+)
B. melitensis 63 ⁄ 9i (–) (–) (+) (+) (+) (–) (+) (+) (+) (–) (–) (+ ⁄ –) (+)
B. melitensis Etheri (–) (–) (+) (+) (+) (–) (+) (+) (+) (+) (–) (+ ⁄ –) (+)
B. suis 1330i (–) (+ +) (+) (–) (–) (–) (–) (+ +) (+) (–) (–) (+) (+)
B. abortus 544i (+) (+ ⁄ –) (–) (+) (+) (–) (+) (–) (+) (–) (+) (+) (+)
B. melitensis Rev.1j (–) (–) (–) (–) (–) (+) (–) (–) (–) (+) (–) (+ ⁄ –) (+)
aResults obtained after incubation with 5% CO2; all the isolates grew with i-erythritol 1 mg ⁄mL added to the basal medium.
b20 mg ⁄L; c100 mg ⁄L; d2.5 mg ⁄L; e5000 IU ⁄L in base medium.
fBauer’s method, all the B. melitensis isolates were positive on Christensen media.
gA, A monospecific antiserum; M, M monospecific antiserum; No isolate was agglutinated by rough (R) Brucella antiserum.
hWith routine test dilution (RTD), no isolate was lysed by R ⁄C phage.
iReference strains; jvaccine strain; IBS, isolated Brucella strain.
(–) negative; (+ ⁄ –) weakly positive; (+) positive; (++) strong positive.
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sis. Susceptibility of B. melitensis to dyes and
penicillin has been reported previously, as well as
the finding that polymorphism of the omp2 porin
gene correlates with dye sensitivity [7,17,18].
This virulent atypical B. melitensis variant could
not have originated from the vaccine Rev.1 strain
(as determined by PCR-RFLP of the rpsl gene with
NciI), although some of its phenotypic character-
istics resembled the vaccine strain. The variant
could have been introduced into the country via
an infected animal, since brucellosis can exist in a
latent form for several years [19], or it could be a
new adaptation variant of B. melitensis.
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